Connect with us

Vyvanse (lisdexamfetamine)


Lisdexamfetamine (or VYVANSE®) is mainly prescribed to treat attention deficit hyperactivity disorder and binge eating disorder.

Status: ACTIVE

Class: Phenethylamine Stimulant

FDA Approval: 2007

Controlled Substance: Schedule II

Dosage Forms: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg

Biological Half-life: ≤1 hour (prodrug), 9-11 hours (d-amphetamine)

Side Effects: Dizziness, dry mouth, diarrhea, constipation, loss of appetite, weight loss, upper stomach pain, insomnia, anxiety, irritability

Precautions: High-risk for psychological dependency

Routes of Administration: Oral

Pregnancy Category: C (US)

  www.who.int

Advertisement

© 2018 Mental Daily. All Rights Reserved.
Our content is for informational purposes and should not be used as medical or treatment recommendation.